# A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

> **NCT05848011** · PHASE2 · COMPLETED · sponsor: **MacroGenics** · enrollment: 154 (actual)

## Conditions studied

- Androgen-Independent Prostatic Cancer
- Androgen-Independent Prostatic Neoplasms
- Prostate Cancer Recurrent
- Androgen-Insensitive Prostatic Cance
- Androgen-Resistant Prostatic Cancer
- Hormone Refractory Prostatic Cancer
- Immunotherapy
- Immune Checkpoint Inhibitor
- Inhibitory Checkpoint Molecule

## Interventions

- **BIOLOGICAL:** lorigerlimab
- **DRUG:** docetaxel
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05848011
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-28
- **Primary completion:** 2026-02-19
- **Final completion:** 2026-03-16
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848011, "A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05848011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*